Drugs aren’t treating the pain of their own high cost

  • Monday, March 24, 2014 2:03pm
  • Opinion


I take a generic drug, a little yellow pill that’s been produced for decades, to control blood pressure. I started taking it long before the day I turned 65, which happened to coincide with the beginnings of the great recession that effectively reduced the value of our savings and our house. 

If that weren’t enough, my blood pressure was further challenged by certain elected leaders who somewhat hysterically proclaimed that it was time to cut Medicare and Social Security benefits. 

Oh my, what are people thinking? But in all the upheaval, I still had my little yellow pill to quell the violence of a blood pressure that was simply responding in kind to the events of the day. Some stability existed after all in $4 a month yellow pills.

Then one day last year I went as usual to pick up my 90-day supply and was told the pharmacy didn’t have it. Say what? How could you not? Moreover, why didn’t you call me, warn me that this perceived lifeline was disappearing? 

“Oh, you called my doctor to order something else and not me?” (Hear internal scream here which apparently the pharmacist did because she said, “We don’t have time to call everyone when this happens.”) 

Besides being annoyed that a call to me, the customer, would be a distraction, I was more stunned that I didn’t have my little yellow pills. 

My next step was to call my former pharmacy (I changed because I mistakenly thought my new Medicare Part D plan required it) who had the little yellow pill and would call my now former pharmacy to transfer the prescription.

I learned later through a little research and articles that began appearing that certain long-used generic drugs were in short supply. It seems that there is little money in it for manufacturers. 

Surely health insurers who were telling the public to get the lowest cost-effective drug, sometimes just the lowest cost, would have some say or clout in working with manufacturers. After all, there are more expensive drugs being developed every day for other conditions. 

Almost as if someone heard me ask the question and thought I needed a bit of humbling, I became privy to a problem far worse than mine. I had come to the pharmacy to pick up my prescription and was waiting respectfully behind a woman being served. She was frantically waving her arms and pacing. A pharmacist and pharmacy staff were trying to comfort her by assuring her she would receive her medicine — just not today. 

In her anguish, she turned and headed toward me and I saw the very worried face of this woman of advanced years with a slightly crooked body that seemed propelled by fear and anger. Her eyes were rimmed in red partly due to her age and partly her emotional stress. 

“I have cancer and I have to have my medicine or I will die,” she shouted to me. Oh, man, how much I wanted to help her, hold her and how utterly powerless I felt. I could only agree how terrible this was for her. 

Unlike my medicine, hers was expensive and apparently not produced by many drug manufacturers. Her worry was so much greater than mine, but we both were in the untended weeds of insurance and drug manufacturing. It seemed we were the collateral damage of a failed strategic partnership between government and corporate interests.

Fast forward about nine months to this May. I went to my pharmacist for my little yellow pills and was shocked to learn the price had increased 150 percent. I was able to ask why despite the fact my jaw was somewhere below the counter. 

“You will have to call your insurance company,” she kindly said. 

So I did and they said I had to call my pharmacy about the price increase.

So I did. “It’s the insurance company trying to get your deductible.” The clerk reasoned that the insurance company sets the price and gets whatever money I pay. Further the clerk said I would have to call the insurance company.

So I did. I learned, and frankly I feel a bit, OK a lot, stupid that I didn’t connect these dots before. My money goes to the insurance company who then pays the drug manufacturer for the drug at some prearranged cost and pays the pharmacy a prearranged dispensing fee. 

It dawned on me that the insurance company could set the price at any price and who was around to question it.

I liked the insurance representative on this call because she was the only one who thought I had a reason to question the increase. She made the effort to find out the reason for the increase and actually called me back the next day. She said the drug manufacturer increased the cost. 

What possible reason is there for a 150-percent cost increase to the consumer for a generic drug that probably costs pennies a pill to manufacture? 

Here in the weeds I have no way of finding out the answer to that question. My next calls are to elected leaders who no doubt will go to great lengths to get me the answer. I will keep you posted.

Bertha D. Cooper is retired from a 40-plus year career as a health care administrator focusing on the delivery system as a whole. She still does occasional consulting. Reach her at columnists@sequimgazette.com.

More in Opinion

Letters to the editor — Dec. 5, 2018

Do right by our youth with new field Nathalie Torres worked hard… Continue reading

Guest opinion: On civility and power, Part II

How can we have civil conversations about complicated issues? What specific steps… Continue reading

Think About It: Light, dark sides of giving

I thought I’d better write this column early in the season, lest… Continue reading

From the Back Nine: Unexpected pride

I’ve been thinking about Pride. Not a pride of lions, or “Pride… Continue reading

Guest opinion: Move forward on water quality standards

In an unfortunate reversal, the U.S. Environmental Protection Agency has decided to… Continue reading

Guest opinion: Tribes release habitat recovery strategy

“As the salmon disappear, so do our cultures and treaty rights. We… Continue reading

Guest opinion: A billion here, a billion there …

Fifty billion dollars. It will soon be the subject of many conversations… Continue reading

Guest opinion: Reducing wildfire risk is imperative

While massive wildfires are historic, they are more dangerous today. As our… Continue reading

Guest opinion: Costs matter in hiring

While both sides argue over the merits of Seattle’s escalating minimum wage,… Continue reading

Most Read